SBIR Phase I: High Throughput Screening of Multivalent Drugs and Nanomedicine

SBIR第一期：多价药物和纳米药物的高通量筛选

• 批准号: 0810474
• 负责人: Athena Guo
• 金额: --
• 依托单位: MICROSURFACES INC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-07-01 至 2009-05-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0810474&HistoricalAwards=false
• 关键词: SBIR; Phase; Throughput; Screening; Multivalent

This Small Business Innovation Research Phase I project develops cell membrane mimetic-microarrays for high-throughput screening and analysis of multivalent drug candidates, particularly nanomedicine. Traditional drugs based on mono-valent and high-affinity interactions can lead to non-specific side effects and toxicity. Advances in synthetic and processing techniques for nanoparticles (inorganic, organic, dendrimer, polymer, liposomes, and etc.) have made available an increasing library of drug candidates that incorporate multivalent surface functionalities for targeting specific cells. The proposed cell membrane mimicking microarrays will be based on an air-stable and fluidic supported lipid bilayer system; the robustness of the proposed membrane microarrays greatly simplifies manufacturing, product distribution, and usage. This product will be of high value to pharmaceutical companies and research institutions that are involved in multivalent and nanomedicine development as well as fundamental research on cell-cell interactions. The broader impacts of this research are contributions to drug development and human health. Nanomedicine is a $7 billion market today and growing at double digits annually. While pharmaceutical companies, biotech startups, and academic laboratories are actively developing nanoparticle-based therapies, there are no products that provide high-throughput analysis of these potential drug candidates. The proposed research will allow development of a superior product to meet the needs for large-scale screening of multivalent drug candidates and, in return, accelerate the development of nanomedicine.

这个小型企业创新研究阶段I项目开发了细胞膜模拟微阵列，用于对多价候选药物（尤其是纳米医学）进行高通量筛查和分析。基于单价和高亲和力相互作用的传统药物会导致非特异性副作用和毒性。纳米颗粒的合成和加工技术的进步（无机，有机，树枝状聚合物，聚合物，脂质体等）已提供了越来越多的候选药物库库，这些库库构成了用于靶向特定细胞的多价表面功能。所提出的模仿微阵列的细胞膜将基于空气稳定的液体支持的脂质双层系统。拟议的膜微阵列的鲁棒性极大地简化了制造，产品分销和使用。该产品对于涉及多价和纳米医学开发以及细胞细胞相互作用的基本研究的制药公司和研究机构将具有很高的价值。这项研究的更广泛影响是对药物开发和人类健康的贡献。纳米医学今天是一个耗资70亿美元的市场，每年增长两位数。尽管制药公司，生物技术初创公司和学术实验室正在积极开发基于纳米颗粒的疗法，但没有任何产品可以对这些潜在的候选药物进行高通量分析。拟议的研究将允许开发出色的产品，以满足对多价候选药物进行大规模筛查的需求，并回报加速纳米医学的发展。